{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:10:15Z","timestamp":1791277815054,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Dabigatran is an oral direct thrombin inhibitor that is Food and Drug Administration-approved for prevention of stroke in patients with atrial fibrillation. No antidote is available for reversal of dabigatran\u2019s anticoagulant effect. Despite limited clinical data, hemodialysis has been suggested as a strategy to remove dabigatran during acute bleeding. This work presents five cases, in which extracorporeal therapy was performed for dabigatran removal in acutely bleeding patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>\n                      The series is comprised of five consecutive cases of patients receiving dabigatran 150 mg\n                      <jats:italic toggle=\"yes\">per os<\/jats:italic>\n                      two times daily who were admitted with life-threatening bleeding between March of 2012 and January of 2013. Dabigatran plasma concentrations ranged from 149 to 1200 ng\/ml. Treatment included administration of blood products to all patients and then, high-flux intermittent hemodialysis alone or followed by continuous renal replacement therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Dabigatran concentrations decreased by 52%\u201377% during intermittent hemodialysis but rebounded up to 87% within 2 hours after completion of dialysis. Initiation of continuous renal replacement therapy after intermittent hemodialysis attenuated the rebound effect in one patient and contributed to a reduction in dabigatran concentrations of 81% over 30 hours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Extracorporeal therapy lowered dabigatran concentrations, suggesting that it removed the drug and may effectively accelerate total clearance, especially in patients with impaired kidney function. The use of prolonged intermittent hemodialysis or intermittent hemodialysis followed by continuous renal replacement therapy is recommended for the management of life-threatening bleeding in patients receiving dabigatran. The advantage of extracorporeal therapy should be weighed against the risk of bleeding with catheter insertion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.01570213","type":"journal-article","created":{"date-parts":[[2013,5,24]],"date-time":"2013-05-24T01:14:25Z","timestamp":1369358065000},"page":"1533-1539","source":"Crossref","is-referenced-by-count":86,"title":["Extracorporeal Therapy for Dabigatran Removal in the Treatment of Acute Bleeding"],"prefix":"10.2215","volume":"8","author":[{"given":"Tripti","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thin Thin","family":"Maw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria M.","family":"Pastor-Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark L.","family":"Unruh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth R.","family":"Hallows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Nolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-12-20230811","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation.","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"R4-12-20230811","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"R5-12-20230811","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-200847010-00005","article-title":"Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"R6-12-20230811","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"R7-12-20230811","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1177\/1076029609343004","article-title":"Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.","volume":"15","author":"Stangier","year":"2009","journal-title":"Clin Appl Thromb Hemost"},{"key":"R9-12-20230811","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMc1111095","article-title":"Acutely injured patients on dabigatran.","volume":"365","author":"Cotton","year":"2011","journal-title":"N Engl J Med"},{"key":"R10-12-20230811","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s13181-011-0178-y","article-title":"Dabigatran: Review of pharmacology and management of bleeding complications of this novel oral anticoagulant.","volume":"7","author":"Ganetsky","year":"2011","journal-title":"J Med Toxicol"},{"key":"R11-12-20230811","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1161\/CIRCULATIONAHA.111.054510","article-title":"Reversal of new oral anticoagulants.","volume":"124","author":"Battinelli","year":"2011","journal-title":"Circulation"},{"key":"R13-12-20230811","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3109\/15563650.2012.721888","article-title":"Hemorrhagic complications associated with dabigatran use.","volume":"50","author":"Chen","year":"2012","journal-title":"Clin Toxicol (Phila"},{"key":"R14-12-20230811","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archinternmed.2011.314","article-title":"The use of dabigatran in elderly patients.","volume":"171","author":"Legrand","year":"2011","journal-title":"Arch Intern Med"},{"key":"R15-12-20230811","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc1112874","article-title":"Bleeding risk with dabigatran in the frail elderly.","volume":"366","author":"Harper","year":"2012","journal-title":"N Engl J Med"},{"key":"R16-12-20230811","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1182\/blood-2011-11-393587","article-title":"Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding.","volume":"119","author":"Warkentin","year":"2012","journal-title":"Blood"},{"key":"R17-12-20230811","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.amjopharm.2012.02.004","article-title":"Clinical challenges in a patient with dabigatran-induced fatal hemorrhage.","volume":"10","author":"Cano","year":"2012","journal-title":"Am J Geriatr Pharmacother"},{"key":"R18-12-20230811","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1345\/aph.1Q747","article-title":"Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment.","volume":"46","author":"Wychowski","year":"2012","journal-title":"Ann Pharmacother"},{"key":"R20-12-20230811","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1097\/MJT.0b013e3182459a79","article-title":"Direct thrombin inhibitors: A case indicating benefit from \u2018plasmapheresis\u2019 in toxicity: A call for establishing \u201cguidelines\u201d in overdose and to find an \u201cantidote!\u201d","volume":"19","author":"Kamboj","year":"2012","journal-title":"Am J Ther"},{"key":"R21-12-20230811","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/j.ajkd.2012.08.047","article-title":"Removal of dabigatran by hemodialysis.","volume":"61","author":"Chang","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"R22-12-20230811","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: An open-label, parallel-group, single-centre study.","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"R23-12-20230811","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1160\/TH12-08-0573","article-title":"Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease.","volume":"109","author":"Khadzhynov","year":"2013","journal-title":"Thromb Haemost"},{"key":"R24-12-20230811","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrneph.2012.160","article-title":"Anticoagulants in atrial fibrillation patients with chronic kidney disease.","volume":"8","author":"Hart","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"R25-12-20230811","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate\u2014a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity.","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"R26-12-20230811","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.110.004424","article-title":"Dabigatran etexilate: A new oral thrombin inhibitor.","volume":"123","author":"Hankey","year":"2011","journal-title":"Circulation"},{"key":"R27-12-20230811","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/15563650.2012.683436","article-title":"The EXTRIP (EXtracorporeal TReatments In Poisoning) workgroup: Guideline methodology.","volume":"50","author":"Lavergne","year":"2012","journal-title":"Clin Toxicol (Phila"},{"key":"R28-12-20230811","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF01062724","article-title":"Pharmacokinetic evaluation of hemodialysis in acute drug overdose.","volume":"6","author":"Takki","year":"1978","journal-title":"J Pharmacokinet Biopharm"},{"key":"R29-12-20230811","first-page":"43","article-title":"Extracorporeal management of valproic acid overdose: A large regional experience.","volume":"17","author":"Singh","year":"2004","journal-title":"J Nephrol"},{"key":"R31-12-20230811","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2125.2006.02667.x","article-title":"Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: A population model analysis.","volume":"62","author":"Liesenfeld","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"R32-12-20230811","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1515\/cclm-2011-0888","article-title":"Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests.","volume":"50","author":"Halbmayer","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"R33-12-20230811","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000081505","article-title":"The ecarin clotting time, a universal method to quantify direct thrombin inhibitors.","volume":"33","author":"Nowak","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"R34-12-20230811","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.","volume":"64","author":"Stangier","year":"2007","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201309000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:43:22Z","timestamp":1786369402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201309000-00012"}},"subtitle":["A Single Center Experience"],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.01570213","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}